×
Oncology Institute Price to Free Cash Flow Ratio 2020-2024 | TOI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Oncology Institute price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
View More
Oncology Institute Price to Free Cash Flow Ratio 2020-2024 | TOI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Oncology Institute price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Elevance Health (ELV)
$93.4B
Cencora (COR)
$48.3B
DiDi Global (DIDIY)
$22.2B
Natera (NTRA)
$22.1B
ICON (ICLR)
$17.7B
Viatris (VTRS)
$16B
Avantor (AVTR)
$14.1B
Revvity (RVTY)
$13.6B
CochLear (CHEOY)
$12.8B
Solventum (SOLV)
$12.2B
BioMerieux (BMXMF)
$11.9B
Medpace Holdings (MEDP)
$10.5B
Charles River Laboratories (CRL)
$10B
HealthEquity (HQY)
$9.1B
Doximity (DOCS)
$9B
Sonic Healthcare (SKHHY)
$8.9B
Bausch + Lomb (BLCO)
$6.9B
Life Times (LTH)
$5.1B
Organon (OGN)
$3.9B
Sotera Health (SHC)
$3.6B
BrightSpring Health Services (BTSG)
$3.3B
Surgery Partners (SGRY)
$2.9B
Concentras Parent (CON)
$2.8B
PACS (PACS)
$2.5B
Alignment Healthcare (ALHC)
$2.3B
Ardent Health Partners (ARDT)
$2.3B
Premier (PINC)
$2.2B
GeneDx Holdings (WGS)
$2.2B
Ryman Healthcare (RYHTY)
$2B
GoodRx Holdings (GDRX)
$1.9B